FY2029 EPS Estimates for Pyxis Oncology Lifted by Analyst

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Analysts at HC Wainwright upped their FY2029 earnings per share estimates for shares of Pyxis Oncology in a research report issued on Tuesday, March 24th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $0.27 per share for the year, up from their prior forecast of $0.21. HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings data on Tuesday, March 24th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.06. The business had revenue of $11.04 million during the quarter.

A number of other equities analysts also recently weighed in on PYXS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Royal Bank Of Canada reduced their price objective on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a report on Thursday, December 18th. Wall Street Zen cut Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Finally, Stifel Nicolaus cut their price target on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Pyxis Oncology Stock Down 4.2%

Pyxis Oncology stock opened at $1.36 on Wednesday. Pyxis Oncology has a 12-month low of $0.83 and a 12-month high of $5.55. The stock has a 50-day simple moving average of $1.52 and a 200 day simple moving average of $2.51. The stock has a market capitalization of $84.67 million, a price-to-earnings ratio of -1.05 and a beta of 1.45.

Institutional Investors Weigh In On Pyxis Oncology

Large investors have recently bought and sold shares of the company. Maia Wealth LLC bought a new position in shares of Pyxis Oncology during the fourth quarter worth $25,000. Engineers Gate Manager LP bought a new position in Pyxis Oncology during the fourth quarter worth about $26,000. Fox Run Management L.L.C. acquired a new position in Pyxis Oncology in the 4th quarter worth $26,000. Avanza Fonder AB bought a new position in Pyxis Oncology during the 4th quarter worth about $31,000. Finally, XTX Topco Ltd acquired a new stake in shares of Pyxis Oncology in the 2nd quarter valued at about $40,000. Institutional investors own 39.09% of the company’s stock.

Trending Headlines about Pyxis Oncology

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: Quarterly results beat expectations — PYXS reported a loss per share of ($0.29) vs. consensus ($0.35) and generated $11.04M of revenue, showing better-than-expected near-term performance. This beats helped validate recent operations and may support longer-term valuation recovery. Earnings Press Release
• Positive Sentiment: Clinical progress — Pyxis completed target enrollment in the Phase 1 monotherapy dose‑expansion of MICVO (micvotabart pelidotin) in 2L+ R/M HNSCC in Q1 2026. Completion of enrollment advances a near‑term clinical catalyst (data/readout) that could materially move the stock if results are positive. Business Update
• Positive Sentiment: Analyst support remains — HC Wainwright reaffirmed a “buy” rating with a $7 price target, signaling ongoing institutional conviction in the story despite the low share price. HC Wainwright Note
• Neutral Sentiment: Short-interest reporting appears anomalous — multiple March filings list 0 shares short and 0.0 days-to-cover (with NaN changes), suggesting a likely data/reporting issue rather than a meaningful shift in short positioning. Treat this as unreliable until corrected by official exchanges.
• Negative Sentiment: Price target cut by a covering analyst — Stifel Nicolaus lowered its target from $9.00 to $8.00 (but kept a “buy” rating). A lower target, even with a buy rating, can pressure sentiment and weigh on the stock in the near term. Stifel Note

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.